With every new gene therapy developed, comes the promise of a cure. That’s why at Genezen; we’re committed to helping companies bring their gene therapies to market, faster. Through established relationships with the leading researchers and institutions, we offer contract viral vector manufacturing, testing, and Phase I/II trial support. Our efficient systems help to ensure you have the expertise and experience needed for your clinical trial.

We can also shave months off your development timelines through our master service agreements with some of the nation’s leading research institutions, including the Vector Production Facility at Indiana University, and the Cincinnati Children’s Hospital Medical Center, among others. Dr. Ken Cornetta is Genezen’s founder and a pioneer in developing viral vector production and technology, with over 30 years of experience. His vision of making vector production readily available informs our work today. No other contract lab has Genezen’s depth of expertise, experience and commitment to viral vector technology.